These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22357662)

  • 1. Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia.
    Maretty L; Sharp RE; Andersson M; Kurtzhals JA
    J Infect Dis; 2012 Apr; 205(7):1173-7. PubMed ID: 22357662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
    Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R
    Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
    Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
    Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Plasmodium chabaudi malaria mortality in mice with nutritional iron deficiency can be reduced by short-term adjunctive iron supplementation.
    Castberg FC; Maretty L; Staalsoe T; Hempel C; Clasen-Linde E; Hviid L; Kurtzhals JAL
    Malar J; 2018 Jan; 17(1):34. PubMed ID: 29338760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
    Froessler B; Gajic T; Dekker G; Hodyl NA
    Arch Gynecol Obstet; 2018 Jul; 298(1):75-82. PubMed ID: 29740690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Bailie GR; Mason NA; Valaoras TG
    Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
    Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
    Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.